Latest Safety News

Renascor Resources has hit key construction milestones at its Australian Government co-funded Purified Spherical Graphite (PSG) demonstration facility, maintaining schedule for on-site commissioning this quarter. The project aims to establish a competitive, HF-free PSG supply chain outside China.

Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.

Genesis Minerals has secured crucial rail agreements that clear the path for developing the Tower Hill open pit gold mine and expanding the Leonora mill, targeting first ore in FY28.

Bindi Metals Limited has announced a non-renounceable entitlement offer of options to raise approximately $46,000, underwritten by CPS Capital Group. The offer includes 46 million options to shareholders and 5 million options to the lead manager, with potential dilution if exercised.

Accent Group Limited reported modest FY25 sales growth with a cautious FY26 outlook, unveiling a strategic partnership to expand Sports Direct stores in Australia and New Zealand.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

Lindian Resources has begun construction of the Tipume accommodation village at its Kangankunde Rare Earths Project in Malawi, marking a critical step towards operational readiness. The modern camp is designed to support up to 90 personnel and is expected to be completed by early 2026.

Mastermyne’s FY2025 AGM reveals resilience amid sector headwinds, operational disruptions, and legal proceedings, while positioning for growth with new leadership and contracts.